YD Bio Ltd
YDES Nasdaq· Services-Medical Laboratories
Last close · Oct 26, 2026
$5.29
KIRA · Stoqly’s AI analyst, in plain words
- YD Bio Ltd had $0.6M of revenue in fiscal 2025, up 16.9% on the year before.
- Its operating margin was −883.3%, down 596.9 pts: of every 100 in sales, about −883 is left after running the business.
- YD Bio Ltd lost $8.3M in fiscal 2025.
- Free cash flow was −$8.0M in fiscal 2025, −1,346.6% of revenue.
- YD Bio Ltd has $6.0M more cash than debt.
Market cap
$353M
P/E
—
Revenue
$0.6M
Net income
−$8.3M
Free cash flow
−$8.0M
Operating margin
−883.3%
YD Bio Ltd in 30 seconds · fiscal 2025
Are sales growing?
+16.9%
Yes. Sales grew 16.9% last year.
Does it make a profit?
−1,392.6%
No. It lost money last year.
Does profit turn into cash?
−1,346.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What YD Bio Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 30, 2026
- Legal name
- YD Bio Ltd
- CIK
- 0002011674
YD Bio Ltd · YDES
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $0.4M | $0.5M | $0.6M |
| Revenue growth | — | 45.8% | 16.9% |
| Gross margin | 43.8% | 30.4% | 28.0% |
| Operating margin | −2.8% | −286.4% | −883.3% |
| Net income | $0.0M | −$1.4M | −$8.3M |
| Net margin | 3.9% | −276.6% | −1,392.6% |
| Diluted EPS | $0.00 | −$0.02 | −$0.12 |
| Cash | |||
| Cash from operations | −$0.1M | −$1.2M | −$6.6M |
| Capital expenditure | $0.0M | $0.1M | $1.4M |
| Free cash flow | −$0.1M | −$1.3M | −$8.0M |
| FCF margin | −16.0% | −254.2% | −1,346.6% |
| Share count change | — | 0.0% | 3.1% |
| Debt and strength | |||
| Cash and short-term investments | $0.1M | $3.1M | $6.0M |
| Debt incl. finance leases | — | — | $0.0M |
| Shareholders' equity | $0.0M | $6.6M | −$2.9M |
| Current ratio | — | 13.2x | 5.9x |
| Interest coverage | −4.7x | −1,827.4x | — |
| Returns and quality | |||
| Return on equity | 59.1% | −42.7% | −445.1% |
| Return on tangible equity | 59.1% | −36.1% | — |
| Piotroski F-score | — | — | 1 |
| Altman Z'' | — | 26.0 | −1.4 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
YD Bio Ltd · YDES
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.29 a share, the company is worth $353M.
Source: SEC EDGAR XBRL filings (CIK 0002011674). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.